Is Amyris Finally Turning a Corner?

One of the single-biggest issues facing investors interested in synthetic biology pioneer Amyris (NASDAQ: AMRS) has been a relatively simple one: product gross margin. The business has routinely spent more money manufacturing products than it has received selling them. In 2019, the business spent $1.27 for every $1 generated from product sales. Needless to say, it's an unsustainable strategy.